Literature DB >> 2158496

Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.

M Akova1, Y Yang, D M Livermore.   

Abstract

Clavulanate and tazobactam (YTR 830) were tested as inhibitors and inducers of the AmpC-type Class I beta-lactamases of Pseudomonas aeruginosa, Enterobacter cloacae, Citrobacter freundii, Serratia marcescens, Morganella morganii and the Ic beta-lactamase of Proteus vulgaris. Both clavulanate and tazobactam inhibited the Pr. vulgaris Class Ic beta-lactamase and potentiated ticarcillin and piperacillin against beta-lactamase derepressed variants of this species. Tazobactam, but not clavulanate, also had some ability to inhibit the AmpC Class I enzymes of M. morganii, C. freundii, Ps. aeruginosa, E. cloacae and S. marcescens. The piperacillin + tazobactam combination, unlike ticarcillin + clavulanate, showed some degree of synergy against most derepressed strains of these species. This behaviour partly depended upon the greater inhibitory activity of tazobactam for the enzymes, but also on piperacillin being easier to potentiate than ticarcillin. The synergy between piperacillin and tazobactam was greatest for M. morganii and C. freundii, least for Ps. aeruginosa and E. cloacae. Unfortunately, it is in the last two species that these enzymes pose the greatest resistance threat. Tazobactam caused little or no antagonism of piperacillin against beta-lactamase inducible species, whereas clavulanate antagonized ticarcillin against beta-lactamase inducible strains of E. cloacae and M. morganii (not other species). The antagonism of ticarcillin was attributable to beta-lactamase induction. The lack of antagonism with the tazobactam+piperacillin combination was related to tazobactam being a weaker inducer than clavulanate, not to piperacillin being less susceptible to antagonism than ticarcillin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158496     DOI: 10.1093/jac/25.2.199

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  28 in total

1.  Tolerability of piperacillin/tazobactam in children and adolescents after high dose radio-/chemotherapy and autologous stem cell transplantation.

Authors:  W Nürnberger; H Bönig; S Burdach; U Göbel
Journal:  Infection       Date:  1998 Jan-Feb       Impact factor: 3.553

Review 2.  A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World.

Authors:  Pranita D Tamma; Yohei Doi; Robert A Bonomo; J Kristie Johnson; Patricia J Simner
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

3.  Cross-Canada survey of resistance of 2747 aerobic blood culture isolates to piperacillin/tazobactam and other antibiotics.

Authors:  K R Forward; P A Franks; D E Low; R Rennie; A E Simor
Journal:  Can J Infect Dis       Date:  1998-01

Review 4.  Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition.

Authors:  Carine Bebrone; Patricia Lassaux; Lionel Vercheval; Jean-Sébastien Sohier; Adrien Jehaes; Eric Sauvage; Moreno Galleni
Journal:  Drugs       Date:  2010-04-16       Impact factor: 9.546

5.  Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.

Authors:  Helio S Sader; Mariana Castanheira; Rodrigo E Mendes; Robert K Flamm; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

6.  Kinetic interactions of tazobactam with beta-lactamases from all major structural classes.

Authors:  K Bush; C Macalintal; B A Rasmussen; V J Lee; Y Yang
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 7.  Evolution of beta-lactamase inhibitors.

Authors:  D M Livermore
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

8.  Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses.

Authors:  Lorna E T Stearne; Doret van Boxtel; Nicole Lemmens; Wil H F Goessens; Johan W Mouton; Inge C Gyssens
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.

Authors:  P Van der Auwera; V Duchateau; C Lambert; M Husson; M Kinzig; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

10.  Biochemical and molecular characterization of three new variants of AmpC beta-lactamases from Morganella morganii.

Authors:  Pablo Power; Moreno Galleni; Juan A Ayala; Gabriel Gutkind
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.